Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

B Banwell, JL Bennett, R Marignier, HJ Kim… - The Lancet …, 2023 - thelancet.com
Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in
patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis …

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management

E Sechi, L Cacciaguerra, JJ Chen, S Mariotto… - Frontiers in …, 2022 - frontiersin.org
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …

Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …

L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

[HTML][HTML] Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM

TV Lanz, RC Brewer, PP Ho, JS Moon, KM Jude… - Nature, 2022 - nature.com
Multiple sclerosis (MS) is a heterogenous autoimmune disease in which autoreactive
lymphocytes attack the myelin sheath of the central nervous system. B lymphocytes in the …

Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies

E Carnero Contentti, J Correale - Journal of neuroinflammation, 2021 - Springer
Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central
nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis …

Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …

A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …

[HTML][HTML] Trial of satralizumab in neuromyelitis optica spectrum disorder

T Yamamura, I Kleiter, K Fujihara… - … England Journal of …, 2019 - Mass Medical Soc
Background Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of
the central nervous system and is associated with autoantibodies to anti–aquaporin-4 …

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

A Traboulsee, BM Greenberg, JL Bennett… - The Lancet …, 2020 - thelancet.com
Background Satralizumab, a humanised monoclonal antibody targeting the interleukin-6
receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder …

[HTML][HTML] Myelin in the central nervous system: structure, function, and pathology

C Stadelmann, S Timmler… - Physiological …, 2019 - journals.physiology.org
Oligodendrocytes generate multiple layers of myelin membrane around axons of the central
nervous system to enable fast and efficient nerve conduction. Until recently, saltatory nerve …

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines

M Filippi, P Preziosa, BL Banwell, F Barkhof… - Brain, 2019 - academic.oup.com
MRI has improved the diagnostic work-up of multiple sclerosis, but inappropriate image
interpretation and application of MRI diagnostic criteria contribute to misdiagnosis. Some …